Arcturus Therapeutics shares are trading higher after the company announced a strategic collaboration with Thermo Fisher Scientific to help support the Phase 3 development and potential commercialization of ARCT-032. Also, Freedom Broker initiated its coverage on the stock with a Buy rating and announced a price target of $27.